NasdaqGM - Nasdaq Real Time Price USD

Cartesian Therapeutics, Inc. (RNAC)

10.40
+0.20
+(1.96%)
As of 9:35:25 AM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
34,173
38,913
26,004
110,777
85,077
Operating Expense
79,032
75,231
111,710
96,239
89,674
Operating Income
-44,859
-36,318
-85,706
14,538
-4,597
Net Non Operating Interest Income Expense
--
7,386
2,131
-3,031
-2,844
Other Income Expense
-550
-48,205
-155,135
23,263
-2,280
Pretax Income
-38,023
-77,137
-238,710
34,770
-9,721
Tax Provision
--
287
-19,000
-609
15,966
Net Income Common Stockholders
-38,310
-77,424
-257,260
35,379
-25,687
Average Dilution Earnings
--
-446
0
--
--
Diluted NI Available to Com Stockholders
-38,756
-77,870
-257,260
35,379
-25,687
Basic EPS
5.34
--
-49.76
7.20
-6.60
Diluted EPS
5.33
--
-49.76
3.00
-6.60
Basic Average Shares
22,398.98
--
5,170.32
4,825.29
3,810.96
Diluted Average Shares
22,480.10
--
5,170.32
4,862.50
3,810.96
Total Operating Income as Reported
-52,438
-43,897
-86,416
14,538
-4,597
Total Expenses
79,032
75,231
111,710
96,239
89,674
Net Income from Continuing & Discontinued Operation
-38,310
-77,424
-219,710
35,379
-25,687
Normalized Income
-37,662
-38,863.31
-76,350.08
17,261.93
-24,011.65
Interest Income
834
7,386
4,964
--
--
Interest Expense
--
0
2,833
3,031
2,844
Net Interest Income
--
7,386
2,131
-3,031
-2,844
EBIT
-85,678
-77,137
-235,877
37,801
-6,877
EBITDA
-83,554
-75,986
-235,034
39,088
-5,625
Reconciled Depreciation
2,124
1,151
843
1,287
1,252
Net Income from Continuing Operation Net Minority Interest
-38,310
-77,424
-219,710
35,379
-25,687
Total Unusual Items Excluding Goodwill
-648
-48,811
-155,826
22,933
-2,295
Total Unusual Items
-648
-48,811
-155,826
22,933
-2,295
Normalized EBITDA
-82,906
-27,175
-79,208
16,155
-3,330
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
-10,250.31
-12,466.08
4,815.93
-619.65
12/31/2021 - 6/22/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BCYC Bicycle Therapeutics plc
8.11
0.00%
 
EWTX Edgewise Therapeutics, Inc.
15.01
+0.82%
 
SYRE Spyre Therapeutics, Inc.
14.75
0.00%
 
JANX Janux Therapeutics, Inc.
24.56
-3.04%
 
XNCR Xencor, Inc.
8.29
+2.24%
 
CNTA Centessa Pharmaceuticals plc
12.31
-1.20%
 
KYTX Kyverna Therapeutics, Inc.
2.2700
-2.16%
 
TCRX TScan Therapeutics, Inc.
1.4611
+11.03%
 
VRDN Viridian Therapeutics, Inc.
12.93
+0.90%
 
NRIX Nurix Therapeutics, Inc.
9.76
+0.31%